According to our new research study on "Therapeutic Vaccines Market Forecast to 2031 - Global Analysis - by Product, Technology, and End User," the market is expected to grow from US$ 1,244.94 million in 2024 to US$ 2,934.57 million by 2031; it is estimated to record a CAGR of 13.0% from 2024-2031. Key factors driving the growth of the therapeutic vaccines market are the rising prevalence of chronic diseases, and increasing investments and funding for vaccine development. However, regulatory challenges hinder the market's growth.

The scope of the therapeutic vaccines market report includes the assessment of the market performance in North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. Asia Pacific is anticipated to register the fastest CAGR in the therapeutic vaccines market from 2024 to 2031. Owing to the growing emphasis on preventive healthcare and the rising availability of therapeutic vaccine, the market is expected to witness growth in the region. Additionally, countries such as India, China, and Japan are estimated to emerge as highly rewarding markets for therapeutic vaccine suppliers in the long run, driven by increasing healthcare investments, rising prevalence of chronic diseases, and growing awareness of immunotherapies, supporting the growth of the therapeutic vaccines market growth in Asia Pacific. In addition, the market in Asia Pacific is expected to continue expanding, driven by technological innovations and an increasing demand for targeted therapies.

China, India, and Japan are three significant contributors to the market growth in this region. According to the WHO, ~4.5 million new cancer cases and 3 million deaths due to cancer were reported in China in 2020. As reported by GlobalData's Pharmaceutical Intelligence Centre, as of August 2024, the country had a development pipeline of 23 distinct cancer vaccines, spanning from Phase I to Phase III clinical trials. Notably, 60% of these vaccines are therapeutic cancer vaccines, primarily being developed by domestic companies. Among these, Rebys, created by Cure & Sure Biotech, is an autologous heat shock protein-gp6 peptide complex that stands out as the first therapeutic cancer vaccine approved in China for multiple oncology indications, including pancreatic, esophageal, gastric, and liver cancers. As these vaccines advance through clinical trials and move toward commercialization, China's role in oncology is poised to grow significantly in the coming years. As a result, China has the potential to emerge as a substantial market and a key innovator in the global war against cancer over the next decade.

In May 2024, WestGene (China), a biotech company, received investigational new drug (IND) approval from the US FDA for its innovative mRNA vaccine-WGc-043. This vaccine targets cancer associated with the Epstein-Barr virus (EBV) and represents a promising development in the realm of therapeutic cancer vaccines. The IND approval permits WestGene to initiate clinical trials involving human participants, marking a crucial step in evaluating the vaccine's safety and efficacy. The introduction of WGc-043 could play a pivotal role in the ongoing battle against cancers linked to the EB virus, which has been implicated in various malignancies, including nasopharyngeal carcinoma and Hodgkin lymphoma. As clinical trials progress, this advancement not only enhances the landscape of cancer treatment but also underscores the growing significance of mRNA technology in developing targeted therapies. The success of WGc-043 could pave the way for new treatment options and inspire further research into mRNA-based interventions in oncology in the country.

Moreover, the surging number of cancer cases and rising geriatric population in Japan are likely to propel the demand for effective treatment options, creating the need for therapeutic vaccines. According to the GLOBOCAN 2022 data released by the WHO, there were ~1.0 million new cancer cases in Japan in 2022. In the same year, cancer-related mortality accounted for ~0.42 million. The Japanese market is unique due to the high prevalence of cancers, which has spurred targeted vaccine development specifically for cancer conditions.

AnGes Corporation, Daicel Corporation, and Funpep Corporation are collaborating with the Department of Health Development and Medicine to advance the development of therapeutic vaccines aimed at treating infectious diseases, lifestyle-related conditions, and intractable diseases, along with novel vaccine formulations to deplete aging cells. This partnership operates within an industry-academic framework, focusing on creating therapeutic vaccines originating from Japan. The collaborative effort seeks to explore novel approaches for targeting aging cells, potentially addressing age-related ailments and enhancing overall health. By engaging in translational research, the team also aims to bridge the gap between laboratory findings and clinical applications, ensuring that their discoveries can effectively translate into practical treatments. This initiative represents a significant step forward in the quest for effective therapeutic solutions, potentially transforming the landscape of vaccine development and improving patient outcomes against various diseases, aiding the therapeutic vaccines market growth. Also, Japan's aging population is a critical factor influencing the demand for therapeutic vaccines. The country has one of the world's oldest populations, with a high incidence of chronic diseases, necessitating easy access to therapies that can manage or treat these conditions effectively. As Japan's healthcare system increasingly focuses on precision medicine and personalized therapies, therapeutic vaccines are expected to play a significant role in managing age-related diseases, offering significant opportunities for developing and adopting therapeutic vaccines.

Furthermore, India has witnessed a significant rise in the number of cancer cases in recent years, prompting the need for innovative therapies. According to data from the Indian Council of Medical Research-National Centre for Disease Informatics and Research (ICMR-NCDIR), in 2022, India recorded 1.46 million new cancer cases, resulting in a crude incidence rate of 100.4 per 100,000 individuals. With India's large and diverse population, the country faces a high incidence of diseases such as cancer, hepatitis, and HIV, all of which can benefit from therapeutic vaccines. India's established vaccine manufacturing infrastructure makes it an attractive destination for both R&D and the production of therapeutic vaccines. The country is already a global leader in vaccine production and supply, and it also has a robust regulatory framework. With therapeutic vaccines gaining attention globally, the country is well-positioned to capitalize on its expertise to produce cost-effective and scalable treatments. Thus, companies with innovative solutions can grab these opportunities to create high-impact therapeutic vaccines that address global and local healthcare challenges, favoring the therapeutic vaccines market growth.

Dendreon, BioNTech SE, Serum Institute of India Pvt. Ltd, Merck & Co Inc, Amgen Inc, ISA Pharmaceuticals BV, INOVIO Pharmaceuticals Inc, Transgene SA, THERAVECTYS SA, and CureVac SE are among the leading companies profiled in the therapeutic vaccines market report.

Based on product, the therapeutic vaccines market is categorized into cancer vaccines, infectious disease vaccines, and others. Based on technology, the market is bifurcated into allogenic vaccines and autologous vaccines. By end user, the therapeutic vaccines market is segmented into hospitals, clinics, and others. Geographically, the market is categorized into North America (US, Canada, and Mexico), Europe (France, Germany, UK, Spain, Italy, and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, South Africa, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Contact Us
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com